Breast Cancer
New adjuvant treatments for breast cancer prove cost-effective
Published in Immunotherapy Weekly, July 4th, 2007
New adjuvant treatments for breast cancer are cost-effective at improving survival, according to two new studies. Published in the August 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the two studies looked at the cost-effectiveness of different drugs for the management of adjuvant therapies for early breast cancer. In a Canadian economic study of estrogen receptor positive breast cancers, switching from tamoxifen to the oral steroidal aromatase inhibitor exemestane (trade name: Aromasin) extended disease free survival at a minimal cost per person. In another of study of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, the addition...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
Source: Immunotherapy Weekly (2007-07-04)
More Articles from Immunotherapy Weekly
- Ankylosing Spondylitis
Remicade data in ankylosing spondylitis show improvement in spinal mobility and spinal inflammation - Fibromyalgia
FDA Approves First Drug for Treating Fibromyalgia - Nanoparticles
Researchers develop buckyballs to fight allergy - Allergies
CIGNA HealthCare Offers Members Convenient Care - Allergies
Hotel Company Launches 'Healthy Meeting' Program - Ankylosing Spondylitis
Remicade Two Year Data In Ankylosing Spondylitis Show Improvement In Spinal Mobility and Spinal Inflammation - More from this issue of Immunotherapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
